Author:
Yu Zhixian,Zhan Yating,Guo Yong,He Dalin
Abstract
AbstractIt has been reported that metabolic disorders participate in the formation and progression of clear cell renal cell carcinoma (ccRCC). However, the predictive value of metabolism-related genes (MRGs) in clinical outcome of ccRCC is still largely unknown. Herein, a novel metabolism-related signature was generated to assess the effect of MRGs on the prognosis of ccRCC patients. Important module MRGs were selected by differentially expressed analysis and WGCNA. Subsequently, the hub MRGs were screened via univariate cox regression as well as LASSO regression. A new metabolism-related signature of 6 hub MRGs (PAFAH2, ACADSB, ACADM, HADH, PYCR1 and ITPKA) was constructed, with a good prognostic prediction ability in the TCGA cohort. The prediction accuracy of this signature was further confirmed in both GSE22541 and FAHWMU cohort. Interestingly, this MRG risk signature was highly correlated with tumor mutation burden and immune infiltration in ccRCC. Notably, lower PAFAH2, a member of 6 MRGs, was found in ccRCC. Knockdown of PAFAH2 contributed to renal cancer cell proliferation and migration. Collectively, a 6-MRG prognostic risk signature is generated to estimate the prognostic status of ccRCC patients, providing a novel insight in the prognosis prediction and treatment of ccRCC.
Funder
clinical research of Wu Jieping Medical Foundation
Wenzhou Municipal Science and Technology Bureau
Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. Rini, B. I., Rathmell, W. K. & Godley, P. Renal cell carcinoma. Curr. Opin. Oncol. 20, 300–306 (2008).
2. Ljungberg, B. et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur. Urol. 67, 913–924 (2015).
3. Hakimi, A. A. et al. Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer: Data from a randomized phase III trial. Cancer Discov. 9, 510–525 (2019).
4. Posadas, E. M., Limvorasak, S. & Figlin, R. A. Targeted therapies for renal cell carcinoma. Nat. Rev. Nephrol. 13, 496–511 (2017).
5. Tucker, M. D. & Rini, B. I. Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma. Cancers Basel 12, 423–613 (2020).